Longport signs $5 million R&D deal

Article

Ultrasound developer Longport of Swarthmore, PA, last month signed an agreement with Healthlink International of Westerville, OH, in which Healthlink will invest $5 million to support Longport’s R&D efforts. The funds will be used to expand the

Ultrasound developer Longport of Swarthmore, PA, last month signed an agreement with Healthlink International of Westerville, OH, in which Healthlink will invest $5 million to support Longport’s R&D efforts. The funds will be used to expand the company’s list of applications for its Longport Digital Scanner (LDS), a portable ultrasound scanner that captures and reproduces images of soft tissue down to 2 cm (SCAN 1/13/99). Healthlink has also purchased an equity interest in Longport, according to the company.

Longport applied for 510(k) clearance for LDS in January, and hopes to receive clearance this month. The company’s application to the Food and Drug Administration covers the use of LDS for dermatological indications, but Longport plans to research other indications, including podiatric, physical therapy, dental, burn treatment, and such oncologic applications as breast and cervical cancer.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.